SAPHRIS

This brand name is authorized in Australia, Canada, Israel, New Zealand, United States

Active ingredients

The drug SAPHRIS contains one active pharmaceutical ingredient (API):

1 Asenapine UNII CU9463U2E2 - ASENAPINE MALEATE

The mechanism of action of asenapine is not fully understood. However, based on its receptor pharmacology, it is proposed that the efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. Actions at other receptors e.g. 5-HT1A, 5-HT1B, 5-HT2C, 5-HT6, 5-HT7, D3, and a2-adrenergic receptors, may also contribute to the clinical effects of asenapine. Read about Asenapine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SAPHRIS Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05AH05	Asenapine	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AH Diazepines, oxazepines and thiazepines
Discover more medicines within N05AH05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 5140M, 5141N
Country: CA	Health Products and Food Branch	Identifier(s): 02374803, 02374811
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6837, 6838
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 15151, 15152
Country: US	FDA, National Drug Code	Identifier(s): 0456-2402, 0456-2405, 0456-2410